The Research Antibodies market was valued at US$3.271 billion in 2019 and is expected to grow at a CAGR of 7.54% over the forecast period to reach a total market size of US$5.441 billion by 2026.
The term "research antibody" refers to the type of protein that is used for a variety of research purposes, such as diagnostics, and even therapeutic research. As a result of these proteins' ability to bind to specific molecular variants, they are used in cell research and development to isolate and identify specific cells. Humans are better able to understand how proteins interact within cells through their study of proteins. As of today, antibodies are among the most important tools for studying the function of proteins in cells. An increased number of neurodegenerative diseases such as Huntington's disease, Multiple Sclerosis, and Parkinson's is encouraging neurobiological research. As geriatrics grow and treatments become scarce, the demand for antibodies for research is also rising. The strategies of developing personalized medicine, progressing therapeutics, and developing novel and effective therapies are being sought now more than ever before. According to the United Nations (UN) data of World Population Prospects for 2019, the world's population will double within 30 years, from 7.7 billion to 9.7 billion, and at the same time, the world will age more rapidly. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%).
There are several factors that have influenced the research antibodies market, including the growing interest in genomics, the development of higher-quality antibodies for research reproducibility, as well as an increase in R&D activities within the life sciences sector. Powered by the increasing demand for tailored medicine and structure-based drug design, the global market for research antibodies is expected to grow rapidly over the next few years. One example is the USD 3.7 million National Institute of Health grant in 2019 to the Washington University School of Medicine for an open-source database that aims to boost cancer genomics and precision medicine.
A significant increase in research and development by various biopharmaceutical and pharmaceutical companies is mainly driving the market. A rapidly growing market is expected to be fuelled in the near future by the availability of technologically advanced diagnostic and therapeutic products utilizing research antibodies. As an example, two pharmaceutical companies, Y-Biologics and Pascal Biosciences Inc., reached an agreement to work together on discovering and developing novel bio-specific antibodies. The agreement calls for Y-Biologics to contribute their new antibody platform technology, ALiCE, and Pascal Biosciences Inc. to utilize the company's antibodies. In January 2018, for example, Abcam Plc. With the intention of acquiring exclusive rights to Spring Bioscience Corporation's product portfolio for research purposes, Spring Bioscience Corporation and Roche signed a definitive license agreement. In total, 243 rabbit monoclonal antibodies optimized for immunohistochemistry are included in the product portfolio. On the same note, Immunoprecise Antibodies Ltd announced in February 2019 that it had celebrated its successful research collaboration with the Foundation for Innovative New Diagnostics (FIND). The goal of this project was to develop rabbit monoclonal antibodies that detect TB biomarkers using the Bcell select platform.
Another factor expected to boost market growth is an increase in the amount of funding provided by government bodies for proteomics and genomics research. Genetic factors contributing to the top causes of death around the world are being identified with the help of genomic technologies. Through its various genome research centers, NIH advanced precision medicine discoveries in 2018. NIH has awarded USD 28.6 million to the 'All of Us' research program to establish three genome centers throughout the country. These market developments will boost the growth of the research antibody market in the forecast period.
It is a complex and time-consuming process to develop monoclonal or polyclonal antibodies since it requires consideration of factors including the antigen against which antibodies will be generated, its specificity and sensitivity, and its reproducibility. Apart from bioreactors and chromatography resins, filtration systems, as well as media and buffers for the downstream, upstream, and purification stages a variety of technology is involved in antibody production. Capital investment is high for such operations, making the whole procedure expensive.
A lucrative market has emerged since COVID-19 emerged. Pharma companies are conducting extensive research and development to develop vaccines, treatment approaches, and diagnostic kits for this pandemic. Research and development activities to develop novel vaccines and treatments have prompted a substantial increase in the demand for research antibodies. Further, several private and public organizations are making strong efforts to develop COVID-19 vaccines and therapeutics. A clinical-stage immunology company based in San Francisco, Vir Biotechnologies, was given $250 million by GlaxoSmithKline to support its COVID-19 antibody-drug development program in 2020. Additionally, USD 14.5 million was awarded to Emergent BioSolutions, an American biopharmaceutical company based in Maryland, to work on a COVID-19 antibody-drug trial in April 2020.
|Market size value in 2019||US$3.271 billion|
|Market size value in 2026||US$5.441 billion|
|Growth Rate||CAGR of 7.54% from 2019 to 2026|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Type, Research Area, Technology, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||ProSci Incorporated, Thermo Fisher Scientific Inc, General Electric, Merck KGaA, ImmunoPrecise Antibodies Ltd, Johnson & Johnson Services, Inc, Rockland Immunochemicals, Inc., ACROBiosystems, Bio-Rad Laboratories, Inc.|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What will be the research antibodies market by 2026?
A1. The research antibodies market is expected to reach a market size of US$5.441 billion in 2026.
Q2. What is the size of the research antibodies market?
A2. Research Antibodies Market was valued at US$3.271 billion in 2019.
Q3. What are the growth prospects for the research antibodies market?
A3. The global research antibodies market is expected to grow at a CAGR of 7.54% over the forecast period.
Q4. How is the global research antibodies market segmented?
A4. The research antibodies market has been segmented by type, research area, technology, and geography.
Q5. What factors are anticipated to drive the research antibodies market growth?
A5. A significant increase in research and development by various biopharmaceutical and pharmaceutical companies is mainly driving the research antibodies market.
Thermo Fisher Scientific Inc
ImmunoPrecise Antibodies Ltd
Johnson & Johnson Services, Inc
Rockland Immunochemicals, Inc.
Bio-Rad Laboratories, Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.